| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 58 | 2022 | 304 | 6.640 |
Why?
|
| Papillomavirus Infections | 34 | 2022 | 149 | 4.310 |
Why?
|
| Cervical Intraepithelial Neoplasia | 32 | 2022 | 84 | 4.260 |
Why?
|
| Papillomaviridae | 32 | 2022 | 90 | 2.530 |
Why?
|
| Human papillomavirus 16 | 12 | 2020 | 24 | 1.280 |
Why?
|
| DNA, Viral | 12 | 2020 | 63 | 1.230 |
Why?
|
| Colposcopy | 19 | 2021 | 63 | 1.150 |
Why?
|
| Cervix Uteri | 16 | 2020 | 65 | 1.140 |
Why?
|
| Adenocarcinoma | 6 | 2019 | 300 | 1.110 |
Why?
|
| Precancerous Conditions | 9 | 2020 | 39 | 1.080 |
Why?
|
| Papanicolaou Test | 7 | 2018 | 25 | 0.960 |
Why?
|
| Vaginal Smears | 15 | 2021 | 45 | 0.960 |
Why?
|
| Uterine Cervical Dysplasia | 7 | 2016 | 37 | 0.900 |
Why?
|
| Female | 88 | 2022 | 15634 | 0.890 |
Why?
|
| Cytodiagnosis | 4 | 2021 | 12 | 0.870 |
Why?
|
| Genotype | 18 | 2020 | 461 | 0.780 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2022 | 165 | 0.780 |
Why?
|
| Adult | 50 | 2021 | 8030 | 0.710 |
Why?
|
| Middle Aged | 41 | 2022 | 7416 | 0.690 |
Why?
|
| Humans | 93 | 2022 | 28884 | 0.690 |
Why?
|
| Sensitivity and Specificity | 14 | 2019 | 524 | 0.620 |
Why?
|
| Carcinoma, Papillary | 2 | 2015 | 18 | 0.600 |
Why?
|
| Early Detection of Cancer | 10 | 2022 | 137 | 0.580 |
Why?
|
| Biomarkers, Tumor | 10 | 2021 | 415 | 0.570 |
Why?
|
| Aged | 32 | 2020 | 5599 | 0.540 |
Why?
|
| Biopsy | 11 | 2018 | 208 | 0.540 |
Why?
|
| Genotyping Techniques | 4 | 2019 | 21 | 0.520 |
Why?
|
| Mutation | 4 | 2020 | 867 | 0.520 |
Why?
|
| Fallopian Tubes | 2 | 2016 | 15 | 0.520 |
Why?
|
| Endometrium | 2 | 2016 | 39 | 0.520 |
Why?
|
| Kidney Neoplasms | 2 | 2015 | 103 | 0.520 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 107 | 0.490 |
Why?
|
| Tumor Virus Infections | 5 | 2006 | 14 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 13 | 0.480 |
Why?
|
| Endometrial Neoplasms | 5 | 2013 | 189 | 0.470 |
Why?
|
| Genetic Variation | 5 | 2020 | 246 | 0.460 |
Why?
|
| Young Adult | 18 | 2020 | 2839 | 0.450 |
Why?
|
| Ovarian Neoplasms | 8 | 2019 | 607 | 0.450 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 122 | 0.440 |
Why?
|
| Adolescent | 19 | 2020 | 3197 | 0.420 |
Why?
|
| Subtraction Technique | 1 | 2013 | 8 | 0.410 |
Why?
|
| Pattern Recognition, Automated | 1 | 2013 | 32 | 0.400 |
Why?
|
| Microscopy | 1 | 2013 | 38 | 0.400 |
Why?
|
| Alphapapillomavirus | 2 | 2017 | 8 | 0.390 |
Why?
|
| Repressor Proteins | 2 | 2011 | 119 | 0.380 |
Why?
|
| Algorithms | 2 | 2015 | 431 | 0.350 |
Why?
|
| Aged, 80 and over | 14 | 2019 | 2065 | 0.350 |
Why?
|
| Uterine Neoplasms | 4 | 2017 | 80 | 0.340 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2014 | 18 | 0.340 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 118 | 0.330 |
Why?
|
| Genome, Viral | 5 | 2020 | 34 | 0.310 |
Why?
|
| Ovarian Cysts | 3 | 2019 | 6 | 0.310 |
Why?
|
| DNA Methylation | 5 | 2018 | 152 | 0.300 |
Why?
|
| Polymerase Chain Reaction | 7 | 2015 | 270 | 0.280 |
Why?
|
| Genital Neoplasms, Female | 2 | 2018 | 67 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 190 | 0.250 |
Why?
|
| Peritoneal Lavage | 3 | 1990 | 3 | 0.230 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 58 | 0.230 |
Why?
|
| Carcinosarcoma | 2 | 2017 | 31 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 472 | 0.210 |
Why?
|
| Neoplasm Grading | 5 | 2017 | 105 | 0.200 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 787 | 0.200 |
Why?
|
| Specimen Handling | 4 | 2015 | 33 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2020 | 631 | 0.200 |
Why?
|
| Leiomyosarcoma | 2 | 2022 | 10 | 0.190 |
Why?
|
| Disease Progression | 8 | 2015 | 477 | 0.190 |
Why?
|
| Cell Nucleus | 2 | 2015 | 138 | 0.180 |
Why?
|
| Carcinoma in Situ | 2 | 2001 | 46 | 0.180 |
Why?
|
| Retrospective Studies | 6 | 2018 | 2635 | 0.180 |
Why?
|
| Neoplasm Staging | 5 | 2016 | 480 | 0.180 |
Why?
|
| Immunohistochemistry | 5 | 2016 | 465 | 0.180 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 36 | 0.170 |
Why?
|
| Prognosis | 6 | 2018 | 811 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 1 | 2001 | 64 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2012 | 21 | 0.160 |
Why?
|
| Granulosa Cell Tumor | 2 | 2019 | 4 | 0.160 |
Why?
|
| Cytidine Deaminase | 1 | 2020 | 8 | 0.160 |
Why?
|
| United States | 5 | 2022 | 2225 | 0.160 |
Why?
|
| Risk Factors | 7 | 2013 | 2127 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2015 | 1469 | 0.160 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1999 | 8 | 0.160 |
Why?
|
| Research | 1 | 2020 | 93 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 1999 | 33 | 0.150 |
Why?
|
| CpG Islands | 2 | 2017 | 26 | 0.150 |
Why?
|
| Hysterectomy | 2 | 2016 | 86 | 0.150 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 50 | 0.150 |
Why?
|
| Adenoma | 1 | 2019 | 61 | 0.150 |
Why?
|
| Genital Diseases, Female | 2 | 1989 | 7 | 0.150 |
Why?
|
| Carcinoma | 2 | 2017 | 74 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 170 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2017 | 194 | 0.140 |
Why?
|
| Phylogeny | 5 | 2020 | 493 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 50 | 0.140 |
Why?
|
| Curettage | 1 | 2017 | 4 | 0.140 |
Why?
|
| African Americans | 1 | 2020 | 352 | 0.140 |
Why?
|
| Human papillomavirus 18 | 3 | 2019 | 6 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 82 | 0.140 |
Why?
|
| Celecoxib | 1 | 2017 | 10 | 0.130 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2017 | 23 | 0.130 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1997 | 2 | 0.130 |
Why?
|
| Struma Ovarii | 1 | 1997 | 1 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 62 | 0.130 |
Why?
|
| Viral Load | 2 | 2019 | 32 | 0.130 |
Why?
|
| Phenotype | 2 | 2017 | 686 | 0.130 |
Why?
|
| Salpingectomy | 1 | 2016 | 8 | 0.130 |
Why?
|
| Glycolysis | 1 | 2017 | 96 | 0.130 |
Why?
|
| Cation Transport Proteins | 1 | 2017 | 60 | 0.130 |
Why?
|
| Peritoneum | 1 | 1996 | 8 | 0.130 |
Why?
|
| Mucous Membrane | 1 | 2016 | 28 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 1997 | 39 | 0.120 |
Why?
|
| Ovariectomy | 1 | 2016 | 53 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 101 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 1997 | 80 | 0.120 |
Why?
|
| Virus Integration | 1 | 2015 | 2 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 8 | 0.120 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2015 | 8 | 0.120 |
Why?
|
| HLA-A2 Antigen | 1 | 2015 | 18 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 179 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 14 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1995 | 10 | 0.120 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 24 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2015 | 668 | 0.120 |
Why?
|
| DNA, Neoplasm | 3 | 2009 | 34 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 58 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 27 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 995 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2015 | 62 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 555 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 483 | 0.110 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2014 | 1 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 1995 | 198 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 8 | 0.110 |
Why?
|
| Vulva | 1 | 2013 | 5 | 0.100 |
Why?
|
| Urine | 1 | 2013 | 14 | 0.100 |
Why?
|
| Microtomy | 1 | 2013 | 2 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 1351 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 465 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2013 | 1032 | 0.100 |
Why?
|
| Polyploidy | 1 | 2013 | 10 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 73 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2013 | 523 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 50 | 0.100 |
Why?
|
| Peptides | 1 | 2015 | 296 | 0.100 |
Why?
|
| Brachytherapy | 1 | 2013 | 54 | 0.100 |
Why?
|
| Endonucleases | 1 | 2013 | 17 | 0.100 |
Why?
|
| Image Enhancement | 1 | 2013 | 59 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 108 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2014 | 128 | 0.100 |
Why?
|
| Neoplasms | 3 | 2013 | 874 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2016 | 2426 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 347 | 0.100 |
Why?
|
| Oklahoma | 5 | 2012 | 1053 | 0.100 |
Why?
|
| Sterilization, Tubal | 1 | 2012 | 6 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2013 | 72 | 0.090 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2012 | 5 | 0.090 |
Why?
|
| Apoptosis | 2 | 2017 | 780 | 0.090 |
Why?
|
| Mass Screening | 4 | 2016 | 158 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 23 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 16 | 0.090 |
Why?
|
| Laser Capture Microdissection | 3 | 2020 | 9 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2012 | 31 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 302 | 0.090 |
Why?
|
| Triage | 2 | 2016 | 34 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2001 | 485 | 0.090 |
Why?
|
| Condylomata Acuminata | 3 | 1987 | 4 | 0.080 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1990 | 2 | 0.080 |
Why?
|
| Choriocarcinoma | 1 | 1990 | 6 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 148 | 0.080 |
Why?
|
| Age Factors | 3 | 2009 | 737 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 163 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 328 | 0.080 |
Why?
|
| Biomarkers | 1 | 2013 | 777 | 0.080 |
Why?
|
| Genes, Viral | 2 | 2009 | 10 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2018 | 1280 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 433 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 490 | 0.080 |
Why?
|
| Microdissection | 1 | 2009 | 15 | 0.080 |
Why?
|
| Pregnancy | 3 | 2021 | 1255 | 0.070 |
Why?
|
| Cell Transformation, Viral | 1 | 2008 | 7 | 0.070 |
Why?
|
| False Negative Reactions | 2 | 2005 | 24 | 0.070 |
Why?
|
| Hemorrhage | 1 | 1990 | 266 | 0.070 |
Why?
|
| Sarcoma | 2 | 1996 | 29 | 0.070 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2008 | 12 | 0.070 |
Why?
|
| Peritoneal Cavity | 1 | 1988 | 13 | 0.070 |
Why?
|
| Molecular Chaperones | 1 | 2008 | 50 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 379 | 0.070 |
Why?
|
| Conization | 1 | 2007 | 11 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2007 | 20 | 0.070 |
Why?
|
| Electrosurgery | 3 | 2012 | 15 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 92 | 0.060 |
Why?
|
| Pathology, Surgical | 1 | 2006 | 4 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2018 | 120 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 377 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 739 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 254 | 0.060 |
Why?
|
| Automation | 2 | 2021 | 21 | 0.060 |
Why?
|
| Artifacts | 2 | 2005 | 51 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2017 | 95 | 0.060 |
Why?
|
| Ovary | 2 | 2019 | 72 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 120 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 518 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2017 | 332 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 104 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 1002 | 0.050 |
Why?
|
| Epithelium | 2 | 1997 | 40 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 236 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2014 | 98 | 0.050 |
Why?
|
| SEER Program | 1 | 2022 | 47 | 0.050 |
Why?
|
| Observer Variation | 1 | 2002 | 46 | 0.050 |
Why?
|
| ROC Curve | 2 | 2013 | 144 | 0.050 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2022 | 2 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2022 | 66 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2022 | 34 | 0.050 |
Why?
|
| Uterine Cervical Diseases | 2 | 2012 | 6 | 0.050 |
Why?
|
| Colonic Neoplasms | 2 | 1997 | 122 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 72 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 572 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 194 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 13 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 1 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 56 | 0.040 |
Why?
|
| Aneuploidy | 2 | 1997 | 21 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 336 | 0.040 |
Why?
|
| Luteinization | 1 | 2019 | 7 | 0.040 |
Why?
|
| Costa Rica | 1 | 2019 | 3 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 40 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1999 | 67 | 0.040 |
Why?
|
| Logistic Models | 2 | 2012 | 410 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 7 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 1999 | 126 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2005 | 1056 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 25 | 0.040 |
Why?
|
| Global Health | 1 | 2019 | 54 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 245 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2018 | 49 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 82 | 0.030 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2017 | 3 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 43 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 32 | 0.030 |
Why?
|
| Histocytochemistry | 2 | 2015 | 20 | 0.030 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2017 | 8 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 166 | 0.030 |
Why?
|
| Simian virus 40 | 1 | 1977 | 8 | 0.030 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 29 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1977 | 37 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 19 | 0.030 |
Why?
|
| Genomics | 1 | 2018 | 125 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 65 | 0.030 |
Why?
|
| Nucleoside-Diphosphate Kinase | 1 | 1997 | 2 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1997 | 14 | 0.030 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 1997 | 16 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 1997 | 10 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 1997 | 8 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1997 | 39 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 68 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 43 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 1996 | 21 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1997 | 120 | 0.030 |
Why?
|
| Cisplatin | 1 | 2017 | 186 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 1996 | 16 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 243 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2015 | 13 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2015 | 7 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 35 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 21 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 422 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2015 | 16 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2015 | 21 | 0.030 |
Why?
|
| Animals | 5 | 2017 | 10699 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 34 | 0.030 |
Why?
|
| Survival Analysis | 1 | 1996 | 288 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 360 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 126 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2015 | 114 | 0.030 |
Why?
|
| Laparoscopy | 1 | 1997 | 156 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 676 | 0.030 |
Why?
|
| Indazoles | 1 | 2014 | 18 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2014 | 54 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 31 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Vaginal Diseases | 2 | 1990 | 5 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 75 | 0.020 |
Why?
|
| Platinum | 1 | 2013 | 18 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2012 | 23 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1995 | 427 | 0.020 |
Why?
|
| Parity | 1 | 2012 | 50 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 464 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 73 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 237 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 8 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 66 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 686 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 65 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 66 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 133 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 43 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2012 | 91 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 202 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 163 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 148 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 465 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 344 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 515 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hemagglutinins, Viral | 1 | 2008 | 3 | 0.020 |
Why?
|
| Mandibular Neoplasms | 1 | 1988 | 5 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2008 | 14 | 0.020 |
Why?
|
| Base Pairing | 1 | 2008 | 25 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 138 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2008 | 33 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 478 | 0.020 |
Why?
|
| Women | 1 | 2008 | 12 | 0.020 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1988 | 1 | 0.020 |
Why?
|
| Salpingitis | 1 | 1988 | 1 | 0.020 |
Why?
|
| Tissue Adhesions | 1 | 1988 | 4 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2008 | 30 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 1988 | 7 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 825 | 0.020 |
Why?
|
| Cardiac Tamponade | 1 | 1988 | 8 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 2008 | 17 | 0.020 |
Why?
|
| Pericarditis | 1 | 1988 | 14 | 0.020 |
Why?
|
| Candidiasis | 1 | 1988 | 27 | 0.020 |
Why?
|
| Postmenopause | 1 | 2008 | 84 | 0.020 |
Why?
|
| Cysts | 1 | 1988 | 23 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 1987 | 24 | 0.020 |
Why?
|
| Vulvar Neoplasms | 1 | 1987 | 25 | 0.020 |
Why?
|
| Vagina | 1 | 1987 | 42 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1988 | 133 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 319 | 0.020 |
Why?
|
| Software | 1 | 2008 | 127 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1988 | 167 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 700 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 140 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 469 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 142 | 0.020 |
Why?
|
| Americas | 1 | 2005 | 5 | 0.020 |
Why?
|
| Asia | 1 | 2005 | 20 | 0.010 |
Why?
|
| Africa | 1 | 2005 | 18 | 0.010 |
Why?
|
| Aleutian Mink Disease Virus | 1 | 2005 | 1 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2005 | 23 | 0.010 |
Why?
|
| Europe | 1 | 2005 | 99 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 147 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 589 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 4808 | 0.010 |
Why?
|
| Rodent Diseases | 1 | 1981 | 4 | 0.010 |
Why?
|
| Gigantism | 1 | 1981 | 1 | 0.010 |
Why?
|
| Vaginal Neoplasms | 1 | 1981 | 12 | 0.010 |
Why?
|
| Neoplasms, Experimental | 2 | 1981 | 58 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1981 | 16 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1988 | 994 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1987 | 548 | 0.010 |
Why?
|
| Time Factors | 1 | 1984 | 1613 | 0.010 |
Why?
|
| Ploidies | 1 | 1977 | 6 | 0.010 |
Why?
|
| Clone Cells | 1 | 1977 | 22 | 0.010 |
Why?
|
| Karyotyping | 1 | 1977 | 25 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1977 | 24 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1977 | 48 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1977 | 90 | 0.010 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 1997 | 2 | 0.010 |
Why?
|
| Cricetinae | 1 | 1977 | 131 | 0.010 |
Why?
|
| Cell Division | 1 | 1977 | 154 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 94 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1996 | 292 | 0.010 |
Why?
|
| Male | 3 | 1997 | 13934 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 77 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1990 | 68 | 0.000 |
Why?
|
| Hemochromatosis | 1 | 1988 | 3 | 0.000 |
Why?
|
| Spinal Neoplasms | 1 | 1988 | 40 | 0.000 |
Why?
|
| Pericardial Effusion | 1 | 1988 | 12 | 0.000 |
Why?
|
| Amphotericin B | 1 | 1988 | 19 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1987 | 2 | 0.000 |
Why?
|
| Recurrence | 1 | 1988 | 326 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1987 | 69 | 0.000 |
Why?
|
| Thecoma | 1 | 1981 | 1 | 0.000 |
Why?
|
| Dysgerminoma | 1 | 1981 | 2 | 0.000 |
Why?
|
| Cystadenoma | 1 | 1981 | 2 | 0.000 |
Why?
|
| Mesothelioma | 1 | 1981 | 4 | 0.000 |
Why?
|
| Fibrosarcoma | 1 | 1981 | 12 | 0.000 |
Why?
|
| Hemangioma | 1 | 1981 | 8 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1981 | 61 | 0.000 |
Why?
|
| Teratoma | 1 | 1981 | 17 | 0.000 |
Why?
|